{"ok":true,"entity":{"id":"humira","name":"Humira","entityType":"product","officialName":"HUMIRA (adalimumab)","canonicalName":"Humira","displayName":"Humira","category":"TNF阻害薬（アダリムマブ）のバイオ医薬品","shortDescription":"Humira（ヒュミラ、adalimumab）は、AbbVieが米国BLAの保有者であるTNF阻害薬のバイオ医薬品で、関節リウマチ、尋常性乾癬、クローン病、潰瘍性大腸炎、化膿性汗腺炎、ぶどう膜炎などの治療に用いられると公式サイトが掲載している。AbbVieは2026年7月31日の第2四半期決算で、2026年第2四半期のHumira世界純売上高を7.56億米ドル（報告ベースで35.9%減）と発表した。","primaryCluster":"pharmaceuticals","parentEntity":null,"verificationStatus":"draft","website":"https://www.humira.com/","updatedAt":"2026-10-29T04:31:31.488Z","secondaryClusters":[],"alias":["HUMIRA","ヒュミラ","adalimumab","アダリムマブ"],"searchKeywords":["ヒュミラ","Humira","adalimumab","アダリムマブ","TNF阻害薬","AbbVie","バイオシミラー","関節リウマチ"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}